SIRT1 and metabolic dysfunction-associated steatotic liver disease: A recent study demonstrated SIRT1 capacity to attenuate hepatic IGF expression through STAT5 deacetylation [238], further supports the notion that SIRT1 can be an effective therapeutic target in suppressing NAFLD progression.